Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.

ABSTRACT: Recurrent pericarditis (RP) is a complex inflammatory disorder associated with adverse outcomes and poor quality of life. After the first episode of acute pericarditis, a non-negligible group of patients will fail to achieve complete remission despite treatment and will be challenged by side effects from the chronic use of medications like corticosteroids. The cause of RP remains unknown in the majority of cases, mainly due to a gap in knowledge of its complex pathophysiology. Over the past 2 decades, the interleukin-1 (IL-1) pathway has been uncovered as a key element in the inflammatory cascade, allowing the development of pharmacological targets known as IL-1 inhibitors. This group of medications has emerged as a treatment option for patients with RP colchicine-resistance and steroid de

SUBMITTER: Lo Presti S 

PROVIDER: S-EPMC8649126 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature